Document is current
Any future updates will be listed below
-
Authors
Patra, Tapas http://orcid.org/0000-0002-3388-1719
Meyer, Keith
Haga, Yuki
Reagan, Erin K. http://orcid.org/0000-0003-3162-4636
Weissman, Drew
Ray, Ranjit
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK122401)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI124429)
- License Information
-
More Information
Article History
Received: 20 August 2022
Accepted: 27 February 2023
First Online: 18 March 2023
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines, as well as developing nucleoside-modified mRNA. D.W. have disclosed those interests fully to the University of Pennsylvania, and has in place an approved plan for managing any potential conflicts arising from licensing of our patents. Other authors do not have competing interests.
